Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 408 Rectal Neoplasms 152 Colonic Neoplasms 150 Pancreatic Neoplasms 114 Stomach Neoplasms 110 Neoplasm Metastasis 88 Neoplasms 74 Esophageal Neoplasms 60 Small Cell Lung Carcinoma 45 Neuroblastoma 42 Lung Neoplasms 42 Glioblastoma 38 Carcinoma, Non-Small-Cell Lung 38 Esophageal Squamous Cell Carcinoma 33 Brain Neoplasms 33 Unspecified Adult Solid Tumor, Protocol Specific 31 Glioma 31 Breast Neoplasms 28 Central Nervous System Neoplasms 27 Adenocarcinoma Of Esophagus 27 Sarcoma 26 Gliosarcoma 22 Astrocytoma 22 Rhabdomyosarcoma 21 Sarcoma, Ewing 18 Adenocarcinoma 18 Gastrointestinal Neoplasms 17 Oligodendroglioma 16 Recurrence 14 Cholangiocarcinoma 14

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × Irinotecan × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡